The global mRNA therapeutics market size was exceeded USD 19.68 billion in 2024 and is expected to be worth USD 42.64 billion by 2034, registering at a CAGR of 8.28% from 2025 to 2034.
In
terms of revenue, the worldwide mRNA therapeutics market has been evaluated at
USD 20.83 billion in 2025. The market sizing and forecasts are
revenue-based (USD Million/Billion), with 2024 as the base year.
The growth of the mRNA therapeutics market is fostered by the innovations in
delivery systems, ongoing advancements in clinical trials, growing demand for personalized
medicine and positive public perception for mRNA-based therapies and vaccines
following the pandemic.
This Report is Readily Available for Immediate Delivery | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/2118
mRNA Therapeutics Market Key Takeaway
• North America led the market by holding 37.21% of market share in 2024.
• The hospitals and clinics segment accounted for the highest market share of 60.15% in 2024.
• The oncology segment held the biggest market share of 57.42% in 2024.
• The prophylactic vaccines segment contributed the highest market share 52.60% in 2024.
mRNA Therapeutics Market Revenue Analysis:
mRNA Therapeutics Market Revenue (USD Million), By Type, 2022-2024
|
By Type |
2022 |
2023 |
2024 |
|
Prophylactic Vaccines |
14,229.94 |
9,770.68 |
10349.05 |
|
Therapeutic Drugs |
13,030.49 |
8,875.65 |
9325.95 |
mRNA Therapeutics Market Revenue (USD Million), By End User, 2022-2024 By End User 2022 2023 2024 Hospitals
& Clinics 16,271.75 11,172.88 11834.51 Research
Organizations 6,741.50 4,594.46 4830.21 Other 4,247.17 2,878.99 3010.28 Market Overview and Industry Potential The
growing potential of mRNA-based therapies in advancing treatment options for
various chronic diseases such as cancer and incurable conditions such as
genetic disorders with targeted strategies drives the market growth. mRNA-based
therapeutics refers to production of an immune response in a dose-dependent
manner after the successful transfection of mRNA (messenger RNA) in an
individual. These therapies are easy to customize and manufacture with improved
accuracy and minimum adverse effects which boosts their market demand. Furthermore,
the rising investments by pharmaceutical companies and governments for
developing innovative mRNA therapies, improvements in mRNA delivery systems, surging
demand for personalized medicine, rapid advancements in clinical trial, increased collaborations among
biopharmaceutical companies and research organizations as well
as in various healthcare settings such as hospitals and the growing therapeutic
applications potential for protein replacement therapy, regenerative medicine and cancer immunotherapy
fosters the growth of the mRNA therapeutics market. Role of Artificial Intelligence in the mRNA Therapeutics Market In
mRNA therapeutics, Artificial Intelligence (AI) can be applied for
enhancing the efficacy and stability of mRNA vaccines. AI used for various
applications such as for designing mRNA sequences, optimization of mRNA vaccines, for predicting patient
responses, in finding potential new therapeutic targets by analysing complex
biological datasets, in personalized medicine and for speeding up the drug
discovery process. Additionally, the advancements in bioinformatics tools and
increased adoption of AI-based systems by various biopharmaceutical companies
and research organizations is driving the market growth. Set up a meeting at your convenience
to get more insights instantly! https://www.precedenceresearch.com/schedule-meeting Major Trends in the mRNA Therapeutics Market Advancements in Delivery Platforms: The
improvements in delivery systems such as the utilization of lipid nanoparticles
(LNPs) for targeting specific cell types with enhanced stability and low
toxicity, incorporation of nanoparticles with functional groups for targeting
cell populations and certain tissues as well as the ongoing investigations for
using exosomes as a natural delivery vehicle for mRNA-based therapeutics is
significantly paving the way for potential applications in various medical
fields. Potential for Personalized Treatments: With
the increased focus on developing genomic data banks by various countries and
research organizations across the globe and the demand for advanced
pharmacogenomics testing platforms is catering the surging demand for
personalized medicine strategies. Additionally, the improved stability and
efficacy in targeted therapies observed with the application of mRNA
therapeutics in various biomedical applications as well as the ongoing research
and rising clinical investigation initiatives for improving patient outcomes
drives the potential of mRNA therapeutics for personalized treatments. mRNA Therapeutics Market Report Coverage Report Coverage Details CAGR
from 2025 to 2034 8.28% Market
Size by 2024 USD
19.68 Billion Market
Size in 2025 USD
20.83 Billion Market
Size in 2034 USD
42.64 Billion Dominated
Region in 2024 North
America Fastest
Growing Region Europe Base
Year 2024 Forecast
Period 2025
to 2034 Segments
Covered Application,
Type, End User, and Regions Regions
Covered North
America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
You can place an order or
ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344 Market Key Regional Analysis: U.S. mRNA Therapeutics Market Size to Reach USD 11.89 Billion by 2034 The
U.S. mRNA therapeutics market size was valued at USD 5.13
billion in 2024 and is anticipated to reach around USD 11.89 billion by 2034,
at a CAGR of 9.00% from 2025 to 2034. North
America dominated the global market with the largest share in 2024. The market
dominance of this region can be attributed to the growing government
initiatives and federal programs promoting the adoption of mRNA therapeutics,
surge in number of clinical trials, advanced healthcare infrastructure,
increased accessibility to gene based therapies, rising investments in R&D
activities for novel therapies, demand for precision medicine and the presence
of major pharmaceutical companies. Europe
held a significant share in the global mRNA therapeutics market in 2024. The
growing demand for mRNA-based therapies and vaccines for various diseases,
rising approvals by the regulatory bodies, presence of key market players,
growing focus on innovative discoveries through commercialization and increased
market competition for expanding product portfolios is significantly boosting
the market growth of this region. Asia
Pacific region is anticipated to witness lucrative growth in the global mRNA
therapeutics market over the forecast period. The market growth of this segment
can be attributed to the growing adoption of advanced healthcare infrastructure
in various developing areas in the region, surging demand for precision medicine, government initiatives
for providing personalized treatments with the development of genomic
libraries, rising investments in biotechnology and the diverse
demographics of the region favouring the conduction of large number of clinical
trials. mRNA Therapeutics Market Segmentation Type Insights The
prophylactic vaccines segment dominated the market with the largest share in
2024. The rising rates of infectious diseases, growing awareness about
vaccination among the people, vaccination drives by various governments, surge
in global tourism, expansion of immunisation programs, increased R&D
activities for innovative vaccines, ongoing clinical trials and advancements in
vaccine technologies drive the market growth of this segment. The
therapeutic vaccines segment is expected to grow rapidly during the forecast
period. The growth of this segment can be attributed to the increased research
activities for unlocking the potential of mRNA- based therapeutic vaccines such
as development of synthetic mRNAs like self-amplifying mRNAs (saRNAs) and
circular mRNAs (circRNAs), advancements in delivery techniques and
incorporation of peptides and polymers for improving the therapeutic
applicability of these vaccines. Furthermore,
rising investments, growing regulatory support and increased collaborations
among biopharmaceutical industries is expected to drive the market growth in
the upcoming years. • For
instance, in February 2025, CSL, a global biotechnology leader and Arcturus
Therapeutics, an American RNA medicines and vaccines biotechnology company
received the marketing authorization for KOSTAIVE (ARCT-154) which is a
self-amplifying mRNA COVID-19 vaccine for individuals of 18 years and older
from the European Commission. Application Insights The
oncology segment accounted for the
largest market share in 2024. The worldwide cancer cases are expected to reach
35 million by 2050 stated by the American Cancer Society in the Global Cancer
Statistics, 2024 report. The
high specificity, flexibility and potential for creating combination therapies
is driving the development of various mRNA-based cancer therapies such as mRNA
encoding cytokines, mRNA cancer vaccines, chimeric antigen receptor CAR-T
cells, tumour suppressing gene therapies and additional combination therapies
for targeted and personalized treatment therapies with enhanced accuracy and
safety. Moreover,
the ongoing clinical trials for various types of cancers, advancements in
delivery platforms such as use of lipid nanoparticles for improved the mRNA
stability and targeted delivery and surging demand for personalized medicine
for combating cancer is fuelling the market growth of this segment. The
infectious disease segment is expected to witness lucrative growth over the
forecast period. The rising incidences of infectious diseases, growing number
of global outbreaks, development of antibiotic resistance in various
populations, surge in clinical trials for
improving patient life, active participation of governments and several
global organizations for preventing the spread of infectious diseases,
increased public awareness and ongoing advancements in mRNA therapeutics for developing
safe and effective therapies is anticipated to boost the market growth of this
segment during the forecast period. End User Insights Hospitals
and clinics segment accounted for the largest market share in 2024. The
increased focus on translational research, rising collaborations with
biopharmaceutical companies for testing and developing novel mRNA-based
therapies and ongoing clinical investigations in key areas such as cancer immunotherapy, infectious diseases and
rare genetic disorders is driving the market growth. Furthermore,
the growing demand for personalized treatments, increased preference of
individuals towards hospitals and clinics for safe and effective treatments as
well as the availability of advanced technologies for diagnosis and treatments
with experts from the healthcare sector is expected to boost the market growth
of this segment. Browse More Insights: 🔸mRNA Vaccines and
Therapeutics Market: https://www.precedenceresearch.com/mrna-vaccines-and-therapeutics-market 🔸Oral Vaccine Market: https://www.precedenceresearch.com/oral-vaccine-market 🔸RNA Therapy Clinical
Trials Market: https://www.precedenceresearch.com/rna-therapy-clinical-trials-market 🔸Oncology Molecular
Diagnostic Market: https://www.precedenceresearch.com/oncology-molecular-diagnostic-market 🔸Nucleic Acid Therapeutics
Market: https://www.precedenceresearch.com/nucleic-acid-therapeutics-market 🔸Cell and Gene Therapy
Market: https://www.precedenceresearch.com/cell-and-gene-therapy-market 🔸RNA Editing Market: https://www.precedenceresearch.com/rna-editing-market 🔸Lipid Nanoparticles
Market: https://www.precedenceresearch.com/lipid-nanoparticles-market 🔸Protein Expression Market:
https://www.precedenceresearch.com/protein-expression-market mRNA Therapeutics Market Top Companies •
Alnylam Pharmaceuticals •
Arcturus Therapeutics •
Argos Therapeutics Inc. •
AstraZeneca plc. •
BioNTech SE •
CRISPR Therapeutics AG •
Curevac AG •
Etherna Immunotherapies •
Ethris GMBH •
GSK plc. •
IN-CELL-ART •
Ionis Pharmaceuticals, Inc •
Moderna Therapeutics •
Nutcracker •
Pfizer Inc. •
Sangamo Therapeutics, Inc. •
Sanofi AG •
Sarepta Therapeutics •
Tiba Biotech •
Translate Bio, Inc. What is Going Around the Globe? • In
January 2025, etherna immunotherapies NV, a technology platform innovating mRNA
and lipid-based nanoparticle (LNP) technologies, declared a strategic alliance
with Dropshot Therapeutics. The collaboration aims at combining the advanced
platforms of both companies for boosting the development of RNA-based
therapeutics for several new drug candidates across various indications. • In
October 2024, Waters Corporation, a global leader in analytical instruments and
software, launched a comprehensive set of sample preparation enzymes, reagents
and waters_connect software for simplifying sequence and modification
confirmation of large molecule RNA therapeutics by utilizing liquid
chromatography-mass spectrometry (LC-MS) analysis method. These bioseparation
tools created by Waters assist in accelerating and improving the development of
novel large molecule RNA-based pharmaceuticals such as CRISPR sgRNA and mRNA
therapeutics, when applied together in a workflow. • In
September 2024, Primrose Bio, a leading biotechnology company and ExPLoRNA
Therapeutics, an innovative biotechnology company developing mRNA vaccines,
technologies and therapeutics declared a strategic alliance with the goal of
development and marketing of mRNA medicines together. Segments covered in the report: By Application •
Oncology •
Respiratory Diseases •
Infectious Diseases •
Others By Type •
Prophylactic Vaccines •
Therapeutic Vaccines By End User •
Hospitals & Clinics •
Research Organizations •
Other By Regions •
North America •
Europe •
Asia-Pacific •
Latin America •
Middle East & Africa (MEA) Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2118 You can place an order or ask any
questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344 Precedence
Research offers exclusive subscription services designed to provide in-depth
data and analytics insights. With a subscription, you gain access to a
comprehensive suite of statistical resources, market intelligence, and research
tools tailored to your business needs. Whether you're looking for industry
trends, competitive analysis, or future market projections, our subscription
plans ensure you stay ahead with reliable, up-to-date information. Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription About Us Precedence
Research is a worldwide market research and consulting organization. We give an
unmatched nature of offering to our customers present all around the globe
across industry verticals. Precedence Research has expertise in giving
deep-dive market insight along with market intelligence to our customers spread
crosswise over various undertakings. We are obliged to serve our different
client base present over the enterprises of medicinal services, healthcare,
innovation, next-gen technologies, semi-conductors, chemicals, automotive, and
aerospace & defense, among different ventures present globally. Web: https://www.precedenceresearch.com Our Blogs: Towards
Healthcare | Towards
Packaging | Statifacts | Towards EV Solutions | Towards Dental | Towards Automotive | Nova One Advisor For Latest Update Follow Us:
Immediate Delivery Available | Buy This Premium Research
Report@ https://www.precedenceresearch.com/checkout/2118
